Condition: Peritoneal Metastases From Gastric Cancer · Sponsor: Erasmus Medical Center
This is a phase II study conducted in three hospitals in the Netherlands (Erasmus MC in Rotterdam, Catharina Hospital in Eindhoven, and the Netherlands Cancer Institute in Amsterdam). A total of 55 patients will take part. The aim is to test whether a new combination treatment is feasible for patients with gastric peritoneal metastases (PM). The treatment includes chemotherapy (intraperitoneal irinotecan and standard systemic therapy such as CAPOX or FOLFOX), and may also include nivolumab or trastuzumab, depending on biomarker results.
This description comes directly from the study's public registry record.
Micha J de Neijs, Bsc · 010 70 39640 · m.deneijs@erasmusmc.nl
Always discuss trial participation with your own doctor first.
| Antoni van Leeuwenhoek | Amsterdam, Netherlands | Recruiting |
| Catharina Hospital | Eindhoven, Netherlands | Recruiting |
| Erasmus MC, University Medical Center Rotterdam | Rotterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07133490